GCI*VIDEO* Mo Khan CEO of hVIVO, 2022 in Review
Mo Khan CEO of (HVO ) discusses some of their highlights in 2022, which includes contracted orders of £80m+, having a client base which includes four of the top 10 largest global biopharma companies and their name change. Mo also outlines his expectations for 2023
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.